Jevtana (cabazitaxel) 60 mg concentrate and solvent for solution for infusion EU/1/11/676/001

Direct Healthcare Professional Communication

Potential for medication error in the preparation of Jevtana

Dear Healthcare Professional, *4th November 2013*

Sanofi Ireland Ltd., in association with the European Medicines Agency and the Irish Medicines Board (IMB), would like to remind you of the appropriate preparation instructions for Jevtana (cabazitaxel):

Summary

- Sanofi has recently been informed of reconstitution errors with Jevtana (cabazitaxel) that could lead to overdose, with an actual dose delivered that is 15 % to 20% higher than the prescribed dose.
- Jevtana reconstitution requires a two-step dilution. Both the cabazitaxel concentrate vial and the solvent vial contain an overfill to compensate for liquid loss during preparation.
- The overfill ensures that after dilution of the concentrate with the **entire** contents of the accompanying solvent vial, there is an initial diluted solution, called "premix" or "concentrate-solvent mixture", containing 10 mg/mL Jevtana.
- Errors in administered doses have occurred due to an inappropriate reconstitution in the first step where the nominal volume of the solvent vial (4.5 mL) was transferred to the concentrate vial, instead of the entire content, leading to a higher dose of Jevtana delivered;
- The anticipated complications of overdose would consist of exacerbation of adverse reactions as bone marrow suppression and gastrointestinal disorders (see section 4.9 of the SmPC).

	Concentrate vial label	Solvent for dilution vial label
		
Nominal volume **Content of cabazitaxel per nominal volume**	1.5 mL 60 mg cabazitaxel	4.5 mL
Actual fill volume **Content of cabazitaxel per fill volume**	1.83 mL 73.2mg cabazitaxel	5.67 mL

Appropriate preparation instructions

The correct preparation of the infusion solution of Jevtana requires two dilution steps:

1- **Initial dilution of the concentrate**: **Always transfer the ENTIRE content of the solvent vial** to the concentrate in order to reach a concentration of 10 mg/mL in the premix.

2- **Preparation of the infusion solution:** From this premix, the required volume should be taken and injected into the infusion container in accordance with the intended dose of Jevtana to be administered to the patient.

Where an automated software system is used to compound Jevtana, it must be ensured that the system is set up to allow withdrawal of the entire content of the solvent vial for adding to the concentrate vial, in order to ensure a concentration of 10 mg/ml in the premix.

Further information

Jevtana 60 mg concentrate and solvent for solution for infusion was approved in the European Union on 17th March 2011 and is indicated in combination with prednisone or prednisolone for the treatment of metastatic hormone-refractory prostate cancer (mHRPC) in patients previously treated with a docetaxel containing regimen. The product was launched in the EU in April 2011.

Detailed information on Jevtana is available on the website of the European Medicines Agency (EMA): http://www.ema.europa.eu/ema/

Please share this information with relevant colleagues and healthcare personnel.

Call for reporting

Any adverse events experienced by patients should be reported to Sanofi Ireland Ltd. directly using the contact details below or to the Pharmacovigilance Section of the IMB using the yellow-card reporting system, the on-line reporting function on the IMB website (www.imb.ie) or alternatively by contacting the IMB at 01 6764971.

Company contact point

For further information please contact:
Sanofi Ireland Ltd., 18 Riverwalk, Citywest Business Campus, Dublin 24
Tel: 01-4035600, Email address: IEmedinfo@sanofi.com

Yours sincerely,



Dr. Velichka Valcheva MD
Medical Director